Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
By C. Thiede, Christine Steudel, B. Mohr, M. Schaich, U. Schäkel, U. Platzbecker, M. Wermke, M. Bornhäuser, M. Ritter, A. Neubauer and 2 more. Blood, 2002
1,806 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/feef0f6f449e9e54b0bfa93b63b2185f04403769
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, neutral): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. (2003, background): “A recent study has shown that an increased ratio of FLT3-ITD relative to FLT3-WT confers a poorer prognosis and that the FLT3-WT allele is absent in a minority of patients ((24)).”
- The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. (2008, neutral): “Unknown 78 63 (81) 8 (10) 6 (8) 1 (1) — 58 36 (62) 22 (38) —”